Provenge Tide Lifts All Immunotherapies; Price Cheers Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts scramble to revise revenue forecasts upward after Dendreon releases high-end price and plans to go it alone in Europe
You may also be interested in...
With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use
Sanofi-Aventis gained a fast approval for its chemotherapy Jevtana (cabazitaxel) - just 11 weeks after the final filing in a rolling submission for second-line treatment of advanced hormone-refractory prostate cancer. But the company is also positioned for a quick expansion to the first-line setting
With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use
Sanofi-Aventis gained a fast approval for its chemotherapy Jevtana (cabazitaxel) - just 11 weeks after the final filing in a rolling submission for second-line treatment of advanced hormone-refractory prostate cancer. But the company is also positioned for a quick expansion to the first-line setting
Provenge Nod Lifts Spirits And Stocks, But Also Sets High Bar For Success
Approval of Dendreon's Provenge is a major achievement and a shot in the arm for the growing field of therapeutic cancer vaccines, but it also serves as a reminder of the high bar for clinical and regulatory success in uncharted territory